PMID- 28597670
OWN - NLM
STAT- MEDLINE
DCOM- 20190401
LR  - 20190401
IS  - 1210-7875 (Print)
IS  - 1210-7875 (Linking)
VI  - 53
IP  - 2
DP  - 2017 Spring
TI  - [Identification of an optimal algorithm for effective diagnostics of non-small 
      cell lung cancer with ALK gene rearrangement - implementation of the method and 
      practical experiences with routine diagnostics].
PG  - 89-96
AB  - The aim of the retrospective part of the study was a) to select an optimal clone 
      of immunohistochemical (IHC) antibody against the ALK protein with specificity 
      and sensitivity high enough to use this antibody as a screening method for 
      selecting non-small cell lung cancer (NSCLC) cases for fluorescence in situ 
      hybridization (FISH) testing of ALK gene rearrangement and b) to determine the 
      diagnostic yield of "small" biopsies i.e. endobronchial, transbronchial and 
      transthoracic biopsies and cytoblocks for ALK gene rearrangement testing. The 
      best IHC method of ALK protein detection (clone D5F3, dilution 1:100, Cell 
      Signaling Technology, Danvers, MA, USA) was then verified in prospective routine 
      testing of patients with NSCLC. ALK status was correlated with tumor morphology 
      and clinical data. In the retrospective part of the study, 170 EGFR-nonmutated 
      cases of NSCLC were IHC and FISH tested. In the prospective part, 557 cases of 
      NSCLC were tested by IHC and 76 by FISH. There were 8/154 (5.2%) cases with ALK 
      gene rearrangement detected in the retrospective part and 24/557(4.3 %) in the 
      prospective part. Sensitivity and specificity of the best IHC method were 100 % 
      and 99 % in the retrospective part and 100 % and 80 % in the prospective part. 
      The diagnostic yield of "small" biopsies was between 74 - 80 % retrospectively, 
      depending on IHC variant, and 88 % prospectively. No case with ALK gene 
      rearrangement detected prospectively had EGFR mutation. A high diagnostic yield 
      confirms that ALK status testing can be used in this type of specimen. A 
      prevalence of 5.2 % in the retrospective part (EGFR-nonmutated cases) and 4.3 % 
      in the prospective part (without known EGFR mutation status), tumor morphology 
      (solid and acinar type, mucinous type or at least partial mucin production 
      (extra- and/or intracellular) as well as lower average age and male/female ratio 
      of patients with ALK positive tumors in the prospective part (57.5 y vs. 65.2 y, 
      8 men and 16 women vs. 336 men and 197 women) are consistent with global data.
FAU - Rozkos, Tomas
AU  - Rozkos T
FAU - Ryska, Ales
AU  - Ryska A
FAU - Nova, Marketa
AU  - Nova M
FAU - Hornychova, Helena
AU  - Hornychova H
FAU - Krbal, Lukas
AU  - Krbal L
FAU - Matej, Radoslav
AU  - Matej R
FAU - Laco, Jan
AU  - Laco J
LA  - cze
PT  - Journal Article
TT  - Stanoveni optimalniho vysetrovaciho algoritmu pro efektivni vyhledavani 
      nemalobunecnych karcinomu plic s prestavbou genu ALK - zavedeni metodiky 
      a prakticke zkusenosti z rutinniho vysetrovani.
PL  - Czech Republic
TA  - Cesk Patol
JT  - Ceskoslovenska patologie
JID - 0050734
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - *Adenocarcinoma
MH  - Algorithms
MH  - *Anaplastic Lymphoma Kinase/genetics
MH  - *Carcinoma, Non-Small-Cell Lung/diagnostic imaging/genetics
MH  - Female
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - *Lung Neoplasms/diagnosis/genetics
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Receptor Protein-Tyrosine Kinases
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Non-small cell lung cancer - NSCLC - ALK - Immunohistochemistry - FISH.
EDAT- 2017/06/10 06:00
MHDA- 2019/04/02 06:00
CRDT- 2017/06/10 06:00
PHST- 2017/06/10 06:00 [entrez]
PHST- 2017/06/10 06:00 [pubmed]
PHST- 2019/04/02 06:00 [medline]
AID - 61094 [pii]
PST - ppublish
SO  - Cesk Patol. 2017 Spring;53(2):89-96.